Envoy Medical, Inc. Income Statement
COCH|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Envoy Medical, Inc. reported $225,000 in revenue and $21M in net loss for FY2025. Revenue has declined at a 2.6% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $225.0K | $316.0K | $237.0K |
| Cost of Revenue | $742.0K | $789.0K | $498.0K |
| SG&A Expense | $6.8M | $7.3M | $2.6M |
| R&D Expense | $10.2M | $9.0M | $5.0M |
| Operating Income | -$19.3M | -$18.4M | -$8.7M |
| Interest Expense | $816.0K | - | - |
| Net Income | -$20.8M | -$29.9M | -$15.9M |
| EPS (Basic) | -$1.49 | -$2.54 | -$1.57 |
| EPS (Diluted) | -$1.49 | -$2.54 | -$1.57 |
| Shares Outstanding | 18.8M | 12.3M | 19.5M |
| Operating Margin | -8558.2% | -5809.8% | -3673.4% |
| Profit Margin | -9242.2% | -9469.0% | -6718.6% |